galectin-3

galectin-3

A 30-kD protein, a beta-galactosidase-binding lectin encoded by LGALS3 on chromosome 14q22.3, which is thought to be involved in cell growth, adhesion, acute inflammation (neutrophil activation and adhesion, chemoattraction of macrophages, and activation of mast cells), mRNA splicing and processing, and apoptosis.

Normal expression
Mainly in the nucleus of epithelial and immune cells, neutrophils, and vascular endothelium.

Abnormal expression
Over-expression is linked to malignant transformation and metastases in carcinomas of the breast, colon, tongue, liver, and thyroid.
References in periodicals archive ?
Galectin's lead drug,GR-MD-02 is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases.
In fact, a study from the Karmanos Cancer Institute at Wayne State University linked galectin-3 to a number of negative cancer characteristics, including aggressiveness, growth, dissemination of cancer cells through the bloodstream, and tumor growth.
The present study was designed to investigate the role of galectin-3 (Gal-3), an important regulator of multiple apoptotic pathways.
Background: Galectin-3 (Gal-3) plays a role in the mechanisms underlying ocular venous malformation.
Our objective was to investigate the role of Galectin-3 in fine needle aspirates of thyroid nodules as a prospective diagnostic marker and consequently its ability to differentiate benign from malignant neoplasms.
As a potentially novel biomarker, regarding the underlying pathophysiology, galectin-3, a soluble [beta]-galactoside binding lectin, affects the vascular integrity in multiple ways.
BGM's BGM Galectin-3 is a diagnostic test, which measures galectin-3 levels in blood plasma or serum.
Galectin-3 is an animal lectin associated with tumor adhesion, angiogenesis, progression, and metastasis and binds to [beta]-galactoside.
Galectin-3 plays a major role in diseases that involve scaring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system.
Galectin-3 is a member of the lectin family, expressed predominantly by macrophages.
Bristol-Myers Squibb and Galecto Biotech AB announced that the firms, along with the Galecto stakeholders, have entered into a deal that provides the former with the exclusive option to buy Galecto Biotech AB and gain global rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in first phase of development to treat idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions.